Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Medically reviewed by Brendan Camp, MD Hives and eczema are two of the most common skin disorders. Hives, clinically known as ...

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

For children with atopic dermatitis (AD), early childhood stressful life events are associated with an increased risk for disease activity, according to a study published online Jan. 28 in the Journal ...

Dupixent is already approved in the US for a variety of indications, going back to eczema in 2017 (and most recently for the treatment of the rare skin condition prurigo nodularis), but its ...

Advanced atopic dermatitis, commonly known as eczema, is a chronic condition that leads to itchiness, inflammation, redness, and flaking of the skin. Though it’s not contagious and the disease can be ...

Historian Tsuyoshi Hasegawa’s new book examines the self-destruction of the autocratic Russian dynasty. The government’s ban is the latest in a string of prohibitions on Chinese technology ...

We’re sorry, this feature is currently unavailable. We’re working to restore it. Please try again later.